1.2. Pediatrics

Safety and efficacy of enoxaparin for use in children younger than 18 years of age have not been established1-3. Dalteparin is FDA approved to treat VTE to reduce VTE recurrence in pediatric patients greater than or equal to 1 month of age1,2,4. Dalteparin pediatric dosages are summarized in Table 2. Dosages exceeding these recommendations will be reviewed.

Table 2. Pediatric LMWH Recommended Dosages1,2,4
Treatment Indication Drug Name Maximum Recommended Dosage
Venous thromboembolism treatment Dalteparin
  • 4 weeks to less than 2 years:
    • 150 IU/kg twice daily as starting dose; adjust to maintain anti-Xa level between 0.5-1 IU/mL
  • 2 years to less than 8 years:
    • 125 IU/kg twice daily as starting dose; adjust to maintain anti-Xa level between 0.5-1 IU/mL
  • 8 years to less than 17 years:
    • 100 IU/kg twice daily as starting dose; adjust to maintain anti-Xa level between 0.5-1 IU/mL